How Does BotoxWiki Decide Whether a Product Claim Is Supported?

BotoxWiki uses an evidence-first editorial framework.

The objective is not simply to collect favorable statements about botulinum toxin products. It is to determine:

What is the claim?

What source supports it?

What exactly did the source measure?

In whom was it studied?

How strong and direct is the evidence?

and

How narrowly must the conclusion be written to remain scientifically accurate?

Product information, regulatory status, clinical research and marketing language are therefore treated as different categories of information.

A statement is considered useful only when its wording remains within the boundaries of the evidence supporting it.

Principle 1: Start With the Exact Claim

Evidence appraisal should begin with the claim rather than with the product.

For example:

“Neuronox has been evaluated in randomized clinical trials.”

is one claim.

“Neuronox demonstrated non-inferiority to an active comparator for the primary endpoint in a randomized glabellar-lines trial.”

is a more specific claim.

“Neuronox is superior to all other botulinum toxin products.”

is a much broader claim and would require substantially different evidence.

The broader the claim, the greater the evidence burden.

BotoxWiki therefore aims to write the narrowest clinically useful statement that the available evidence can directly support.

Principle 2: Use the Right Source for the Right Question

Different sources answer different questions.

Official Product Information

Current locally approved product information is the primary source for:

• product identity;

• approved indications;

• labeled dosage;

• administration;

• contraindications;

• warnings and precautions;

• storage;

• preparation or reconstitution; and

• other regulatory product statements.

These facts should not be reconstructed from secondary websites when current official information is available.

Peer-Reviewed Clinical Trials

Clinical studies are used to evaluate questions such as:

• efficacy;

• comparative efficacy;

• treatment response;

• adverse events;

• clinical endpoints;

• onset or duration when actually measured;

• non-inferiority or superiority; and

• outcomes in defined study populations.

Systematic Reviews and High-Quality Reviews

These sources are useful for understanding:

• broader bodies of evidence;

• consistency across studies;

• mechanistic context;

• safety patterns;

• methodological issues; and

• areas of uncertainty.

However, when a product-specific primary trial is available, a review should not replace the primary paper when reporting the exact trial result.

Principle 3: Regulatory Approval and Published Research Are Not the Same Thing

A treatment can be described in a published clinical paper without being an approved indication for that product in every jurisdiction.

Conversely, regulatory labeling may contain information supported by a broader regulatory evidence package that cannot be reduced to one journal article.

BotoxWiki therefore separates:

“studied in”

from

“approved for.”

These phrases should never be treated as interchangeable.

Principle 4: Keep Population, Indication and Endpoint Attached to the Result

Clinical evidence is conditional.

A finding in adults with glabellar lines is evidence about the studied glabellar-line population.

A finding in children with cerebral-palsy-associated spastic equinus is evidence about that therapeutic population.

A result in post-stroke upper-limb spasticity should not be converted into evidence of aesthetic performance.

BotoxWiki therefore follows a simple rule:

Product → indication → population → protocol → endpoint → result.

The result should not be detached from this chain.

Principle 5: Study Design Changes the Meaning of the Evidence

Not all clinical studies answer questions with the same level of control over bias.

Relevant design features include:

• randomization;

• allocation concealment;

• blinding;

• control group;

• active comparator or placebo;

• multicentre design;

• prospective versus retrospective design;

• predefined endpoints;

• predefined statistical analysis;

• sample size;

• follow-up; and

• handling of missing data.

Randomized trials are generally stronger for causal treatment comparisons than uncontrolled case series, but study design alone is not enough.

A randomized trial can still have important limitations.

Principle 6: Evaluate Risk of Bias, Not Just the Journal or Study Label

The word “randomized” does not automatically make every result equally reliable.

Questions include:

Was allocation appropriately generated and concealed?

Were participants, investigators or assessors blinded where feasible?

Were outcome data complete?

Were important protocol deviations reported?

Were prespecified endpoints reported?

Was the analysis appropriate for the study design?

These issues affect confidence in the result.

A prestigious journal name should not substitute for critical appraisal of the methods.

Principle 7: Direct Evidence Is More Useful Than Indirect Evidence for a Specific Claim

If the question is:

“How did Neuronox compare with an active comparator in glabellar lines?”

a direct randomized glabellar study is more relevant than:

• a trial in spasticity;

• a formulation paper;

• an animal study;

• a mechanistic paper; or

• an unrelated study of another BoNT-A product.

Indirect evidence can provide context.

It should not be presented as though it directly answered a question that it did not study.

Principle 8: Read the Primary Endpoint Before the Most Attractive Number

A clinical paper may report many outcomes.

The most favorable number is not automatically the most important result.

BotoxWiki first identifies:

the prespecified primary endpoint

the assessment time point

the response definition

and

the statistical hypothesis.

Secondary and exploratory outcomes are then reported in context.

This reduces selective reporting and cherry-picking.

Principle 9: Report the Denominator and Time Point When They Matter

A percentage without context can be misleading.

For example, the Neuronox glabellar trial reported a week-4 investigator-assessed responder rate of:

93.7% (133/142) for NBoNT/Neuronox

versus

94.5% (138/146) for onabotulinumtoxinA. [1]

The useful statement includes:

• what was measured;

• when it was measured;

• how response was defined; and

• who contributed to the analysis.

“93.7% effective” would be too broad because it removes the endpoint and study context.

Principle 10: Preserve the Statistical Design

A superiority trial, equivalence trial and non-inferiority trial ask different statistical questions.

BotoxWiki does not translate:

non-inferior

into

superior

or

identical.

For non-inferiority studies, interpretation should consider:

• the prespecified margin;

• direction of the treatment difference;

• confidence interval;

• primary endpoint; and

• relevant analysis populations.

This is especially important for Neuronox because several of its published randomized comparative studies used non-inferiority designs. [1–4]

Principle 11: Numerical Superiority Is Not Automatically Statistical Superiority

If product A has a 90.3% response and product B has an 86.2% response, it may be tempting to write that product A performed better.

But if the trial was designed to establish non-inferiority and did not establish superiority, the evidence should not be rewritten as a superiority claim.

BotoxWiki distinguishes:

numerically higher

from

statistically demonstrated superiority.

Principle 12: Avoid Cross-Trial Ranking

Suppose one product reports a 95% response in one study and another reports 90% in another.

The first product cannot automatically be called more effective.

The studies may differ in:

• indication;

• population;

• baseline severity;

• dose;

• injection protocol;

• response definition;

• assessment time;

• outcome assessor; and

• statistical method.

Direct head-to-head evidence is more informative for comparative claims than informal comparison of percentages from unrelated trials.

Principle 13: Product-Specific Units Must Remain Product-Specific

Botulinum toxin potency units are biological activity units and should not be treated as conventional mass units.

A numerical Unit value should not automatically be assumed to have identical biological meaning across different products.

When a head-to-head study evaluates a defined numerical dose relationship, BotoxWiki describes it as:

the studied dose relationship under that protocol.

It does not automatically convert the trial into a universal dose-conversion rule.

Principle 14: Formulation Facts Should Not Be Converted Into Clinical Outcomes

A formulation may differ in:

• excipients;

• neurotoxin preparation;

• manufacturing process;

• associated proteins;

• presentation; and

• potency-assay framework.

These are legitimate product characteristics.

But formulation alone does not prove:

greater efficacy

longer duration

lower diffusion

greater precision

better safety

or

lower immunogenicity.

A clinical claim requires clinical evidence.

Principle 15: Diffusion Claims Require Diffusion-Relevant Evidence

Marketing language frequently uses terms such as:

precise

wide spread

low diffusion

or

stays exactly where injected.

BotoxWiki does not infer a diffusion profile from formulation alone.

Clinical spread can be influenced by dose, volume, injection site, anatomy and technique.

If a study did not directly assess a relevant field-of-effect or spread outcome, its efficacy result should not be converted into a diffusion claim.

Principle 16: Duration Claims Must Reflect What Was Actually Measured

The final follow-up visit is not automatically the duration of effect.

A study ending at week 24 does not prove that every participant maintained benefit for 24 weeks.

Duration claims should specify whether the study measured:

• response at scheduled visits;

• persistence of response;

• time to loss of response;

• time to retreatment; or

• another defined outcome.

BotoxWiki therefore avoids turning follow-up duration into effect duration without supporting data.

Principle 17: Safety Claims Need Their Own Evidence

Efficacy evidence and safety evidence answer different questions.

A treatment meeting an efficacy non-inferiority endpoint does not automatically establish equivalent safety.

Likewise, a numerically lower adverse-event rate does not automatically prove superior safety.

Trial size, duration, event frequency and statistical power all matter.

Rare adverse events may not appear in relatively small trials.

Product-specific warnings and contraindications should therefore remain anchored to current approved product information.

Principle 18: Negative Findings Must Not Become Absolute Claims

Suppose a study reports no positive neutralizing-antibody tests.

The appropriate statement is:

“No positive tests were reported under the study conditions.”

It is not:

“This product does not cause antibodies.”

Similarly:

“No serious adverse events were reported in this trial”

does not mean:

“Serious adverse events cannot occur.”

The wording must preserve the limits of observation.

Principle 19: Consider Precision and Sample Size

A result is more uncertain when based on few participants, few events or a wide confidence interval.

BotoxWiki therefore does not treat a point estimate as exact.

Where confidence intervals materially affect interpretation—especially in non-inferiority studies—they should be reported.

Large percentages from small samples should not automatically be treated as stronger evidence than more precise estimates from larger studies.

Principle 20: Consider Consistency Across Studies—but Do Not Pool Informally

Repeated findings across independent studies can strengthen confidence.

However, results from different indications and endpoints should not simply be averaged.

For example, Neuronox response rates from glabellar lines, blepharospasm and cerebral-palsy spasticity should not be combined into a single “Neuronox efficacy percentage.”

Such pooling would require an appropriate systematic-review or meta-analytic method and sufficiently comparable studies.

Principle 21: Preserve Limitations

Every study has boundaries.

Relevant limitations may include:

• small sample size;

• short follow-up;

• active comparator without placebo;

• limited population;

• single-country recruitment;

• missing data;

• protocol deviations;

• exploratory secondary analyses; and

• limited ability to detect uncommon safety outcomes.

Limitations are not editorial clutter.

They define how far the evidence can reasonably be generalized.

Principle 22: Preserve Funding and Conflict-of-Interest Disclosures

Industry sponsorship does not automatically invalidate a clinical study.

Likewise, absence of industry funding does not automatically make a study methodologically strong.

BotoxWiki evaluates the methods and preserves disclosures separately.

When reported, relevant information may include:

• manufacturer sponsorship;

• author employment;

• consultancy;

• lecture honoraria;

• research support; and

• statistical or contract-research involvement.

Readers should be able to see both the evidence and the context in which it was generated.

Principle 23: Do Not Create Scientific-Looking Scores Without a Validated Method

BotoxWiki does not convert heterogeneous evidence into arbitrary ratings such as:

Efficacy ★★★★★

Safety ★★★★★

Diffusion ★★★★

Naturalness 9/10

unless a transparent, validated and clinically meaningful scoring method supports those numbers.

A star rating can create the appearance of precision while hiding major differences in study quality, indication and endpoint.

Evidence tables are preferable to unsupported rankings.

Principle 24: Separate Fact, Interpretation and Editorial Conclusion

A useful evidence article should make clear which level of statement is being presented.

Source Fact

“The study randomized 314 participants.”

Study Result

“The week-4 responder rates were 93.7% and 94.5%.”

Statistical Interpretation

“The prespecified non-inferiority criterion was met.”

Editorial Interpretation

“This provides product-specific randomized comparative evidence for Neuronox in the studied glabellar-line population.”

These statements are related, but they are not identical.

Keeping them separate reduces overstatement.

Principle 25: “No Evidence Found” Is Different From “Evidence of No Effect”

If BotoxWiki does not identify a validated direct study demonstrating that a product has lower diffusion than another product, the correct statement is:

“The reviewed evidence does not establish lower diffusion.”

It is not:

“The products definitely have identical diffusion.”

Absence of evidence should not be converted into evidence of absence.

Principle 26: Evidence Must Be Current Enough for the Claim

Clinical trial results may remain relevant for many years.

Regulatory information can change.

Therefore, different claims require different update strategies.

Mechanism papers may remain scientifically relevant for long periods.

But information involving:

• approved indications;

• labeling;

• contraindications;

• warnings;

• storage;

• administration; and

• regulatory status

should be checked against the current locally approved product information before publication or revision.

How Does BotoxWiki Evaluate Neuronox Evidence?

Neuronox is evaluated using the same evidence rules.

The product is not treated as superior merely because the website contains a dedicated Neuronox evidence cluster.

Instead, product-specific claims are linked to product-specific sources.

The current evidence set includes published randomized comparative studies in:

moderate-to-severe glabellar lines [1]

essential blepharospasm [2]

cerebral-palsy-associated spastic equinus [3]

and

post-stroke upper-limb spasticity. [4]

Each study is evaluated separately.

What Can the Current Neuronox Evidence Set Support?

Across the four reviewed randomized comparative studies, the primary analyses met their respective prespecified non-inferiority criteria. [1–4]

This supports the statement:

Neuronox has product-specific published randomized comparative clinical evidence across multiple aesthetic and therapeutic settings.

It also supports:

The primary analyses of the four reviewed comparative studies met the prespecified non-inferiority criteria defined for their respective trials.

These statements are evidence-based and traceable.

What Does the Evidence Set Not Automatically Support?

It does not establish that Neuronox is:

the best botulinum toxin

universally superior

universally interchangeable with BOTOX

the longest-lasting

the least diffusive

the safest

or

incapable of inducing neutralizing antibodies.

Each of those would require evidence specifically capable of supporting that claim.

Why Is This Approach Actually Valuable for Neuronox?

Because Neuronox has product-specific human comparative data that can be discussed directly.

There is no need to rely exclusively on broad marketing descriptions.

For example, BotoxWiki can state that:

• 314 participants were randomized in the glabellar Phase III study; [1]

• the week-4 responder rate was 93.7% for NBoNT/Neuronox and 94.5% for onabotulinumtoxinA; [1]

• the essential-blepharospasm trial met its non-inferiority criterion in both ITT and PP analyses; [2]

• the cerebral-palsy trial met its primary non-inferiority criterion in ITT and PP analyses; [3]

• and the post-stroke trial met its primary MAS non-inferiority criterion. [4]

These are stronger editorial building blocks than unsupported adjectives because each statement can be traced to a clinical study.

The BotoxWiki Evidence Workflow

For every important product claim, the editorial process should ask:

1. What exactly is the claim?

2. Is it regulatory, clinical, mechanistic or promotional?

3. What is the most appropriate source?

4. Is there a primary source?

5. Is the source about the exact product?

6. Is it the same indication and population?

7. What is the study design?

8. What is the primary endpoint?

9. What was the prespecified statistical question?

10. What are the actual results?

11. What do the confidence intervals show?

12. What are the important limitations?

13. Are funding and conflicts disclosed?

14. Does the proposed wording go beyond the evidence?

15. Does current local labeling need to be checked?

Only after these questions are answered should the final claim be written.

A Practical Claim Test

Before publication, every major product statement should pass three questions:

Can the Claim Be Traced?

Can the reader identify the source supporting it?

Does the Source Actually Measure the Claim?

A formulation paper cannot by itself prove clinical duration.

An efficacy trial cannot automatically prove low diffusion.

A therapeutic trial cannot automatically prove aesthetic performance.

Is the Wording No Broader Than the Evidence?

If the study demonstrated non-inferiority for one endpoint at one time point, the wording should remain within that conclusion.

If all three conditions are satisfied, the claim is much more defensible.

Frequently Asked Questions

Does BotoxWiki use marketing materials as clinical evidence?

Promotional material may help identify a claim that needs verification, but it should not replace appropriate clinical or regulatory evidence.

Is a randomized trial automatically high-quality evidence?

Randomization is important, but risk of bias, missing data, sample size, directness and study conduct must still be assessed.

Does a published paper prove an approved indication?

No. Approved indications should be checked against current official product information in the relevant jurisdiction.

Can results from different indications be combined?

Not informally. Different populations and endpoints should remain separate unless an appropriate evidence-synthesis method supports pooling.

Does industry sponsorship invalidate a study?

No. Sponsorship should be disclosed, while methodological quality should be evaluated separately.

Does non-inferiority mean superiority?

No.

Can BotoxWiki say Neuronox has randomized comparative evidence?

Yes. Published randomized comparative studies are available across several aesthetic and therapeutic settings. [1–4]

Can BotoxWiki say Neuronox is the best BoNT-A product?

The current evidence set does not establish that claim.

Bottom Line

BotoxWiki evaluates evidence by matching the strength and wording of the claim to the strength, directness and scope of the source.

The framework prioritizes:

current official information for regulatory facts

primary clinical evidence for clinical claims

direct evidence for product comparisons

prespecified endpoints over cherry-picked results

confidence intervals and statistical design where relevant

transparent limitations

and

visible funding and conflict disclosures.

For Neuronox, this approach is particularly useful because published randomized comparative clinical evidence exists across multiple clinical settings. [1–4]

The purpose is not to make the evidence sound stronger than it is.

It is to show precisely where the evidence is strong.

That distinction allows BotoxWiki to make product statements that are specific, transparent, traceable and scientifically defensible.

References

1. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

2. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937.

3. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x. PMID:21087238.

4. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, Bang MS. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. PMID:26030192.

5. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD.

6. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332.

7. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594–2604. doi:10.1001/jama.2012.87802.

8. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.